Multiscale Model Identifies Improved Schedule for Treatment of Acute Myeloid Leukemia In Vitro With the Mcl‐1 Inhibitor AZD5991

• Κύριοι συγγραφείς: Ardeshir Goliaei (Συγγραφέας), Haley A. Woods (Συγγραφέας), Adriana E. Tron (Συγγραφέας), Matthew A. Belmonte (Συγγραφέας), J. Paul Secrist (Συγγραφέας), Douglas Ferguson (Συγγραφέας), Lisa Drew (Συγγραφέας), Adrian J. Fretland (Συγγραφέας), Bree B. Aldridge (Συγγραφέας), Francis D. Gibbons (Συγγραφέας)
• Μορφή: Βιβλίο
• Έκδοση: Wiley, 2020-10-01T00:00:00Z.
• Θέματα: article
• Διαθέσιμο Online: Connect to this object online.

Anticancer efficacy is driven not only by dose but also by frequency and duration of treatment. We describe a multiscale model combining cell cycle, cellular heterogeneity of B‐cell lymphoma 2 family proteins, and pharmacology of AZD5991, a potent small‐molecule inhibitor of myeloid cell leukemia 1...